Clinical Trial Update: Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase I trial combining sodium selenite with docetaxel in castration-resistant prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Sodium selenite (sodium selenite)

Snippet

Sponsor: Sandy Srinivas | Conditions: Urologic Neoplasms, Prostate Cancer | Phase 1 | Status: TERMINATED